Polynovo Ltd

Polynovo operates with a capital structure that includes a total equity of AUD 83.26 million and total liabilities of AUD 44.15 million, resulting in a debt-to-equity ratio of 0.21. The company's liquidity position is characterized by a current ratio of 2.77, indicating a strong ability to meet short-term obligations. However, the company's net cash position is negative after subtracting total debt, which raises some liquidity concerns. In terms of profitability, Polynovo's return on equity (ROE) is 15.87%, and its return on assets (ROA) is 10.37%. These figures suggest that the company is generating a solid return on its equity and assets, which is favorable compared to the industry norms. The company's gross profit margin is 96.0%, indicating a high level of efficiency in its operations. Polynovo's revenue is concentrated in the healthcare services and equipment segment, with no significant geographic diversification reported in the available data. The company's exposure to a single business segment may increase its vulnerability to market fluctuations in the healthcare sector. The company's growth trajectory is reflected in its financial performance, with a net income of AUD 13.21 million and an operating income of AUD 4.97 million. Analysts have provided a mean price target of AUD 1.72, with a median price target of AUD 1.67, suggesting a positive outlook for the company's stock. The risk assessment for Polynovo indicates a medium liquidity risk and a low dilution risk. The company's capital expenditure of AUD -13.93 million suggests a reduction in capital spending, which may be a strategic move to preserve cash. The company's liquidity position is further supported by a market price of AUD 1.245 and a market cap of AUD 860.10 million. Recent events and filings have not indicated any significant changes in the company's operations or financial strategy. The company's financial snapshot and valuation metrics suggest a stable and profitable business model, with a strong equity base and a positive outlook from analysts.